We studied the effect of dyslipidemia induced by poloxamer 407 (300 mg/kg twice a week for 30 days) on cellular composition of the spleen and splenocyte lysosomes in mice. Changes in blood lipid profile included elevated concentrations of total cholesterol, aterogenic LDL, and triglycerides most pronounced in 24 h after the last poloxamer 407 injection; gradual normalization of lipid profile was observed in 4 days (except triglycerides) and 10 days. The most pronounced changes in the spleen (increase in organ weight and number of cells, inhibition in apoptosis, and reduced accumulation of vital dye acridine orange in lysosomes) were detected on day 4; on day 10, the indices returned to normal. Cathepsin D activity in the spleen also increased at these terms. The relationship between changes in the cellular composition of the spleen and dynamics of serum lipid profile in mice in dyslipidemia caused by repeated administrations of relatively low doses of poloxamer 407 is discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
V. M. Loginova, F. V. Tuzikov, N. A. Tuzikova, and T. A. Korolenko, Bull Exp. Biol. Med., 155, No. 2, 284-287 (2013).
A. V. Shurlygina, O. T. Kudaeva, O. P. Kolesnikova, et al., Bull Exp. Biol. Med., 156, No. 1, 73-77 (2013).
F. Antunes, E. Enrique Cadenas, and U. T. Brunk, Biochem. J., 356, Pt 2, 549-555 (2001).
M. A. Bewley, H. M. Marriott, C. Tulone, et al., PLoS Pathog., 7, No. 1, doi: 10.1371/journal.ppat.001001262 (2011).
M. K. Gould, X. L. Vu, T. Seebeck, and H. P. de Koning, Anal. Biochem., 382, No. 2, 87-93 (2008).
G. Dumortier, J. L. Grossiord, F. Agnely, and J. C. Chaumeil, Pharm. Res., 23, No. 12, 2709-2728 (2006).
T. P. Johnston, J. Pharm. Pharmacol., 62, No. 12, 1807-1812 (2010).
T. A. Korolenko, F. V. Tuzikov, M. S. Cherkanova, et al., Can. J. Physiol. Pharmacol., 90, No. 2, 141-153 (2012).
T. A. Korolenko, F. V. Tuzikov, T. P. Johnston, et al., Can. J. Physiol. Pharmacol., 90, No. 11, 1456-1468 (2012).
S. M. Moghimi, Biochim. Biophys. Acta, 1472, Nos. 1-2, 399-403 (1999).
B. Nakken, T. Varga, I. Szatmari, et al., J. Immunol., 187, No. 1, 240-247 (2011).
S. Sharyo, K. Kumagai, N. Yokota-Ikeda, et al., J. Pharmacol. Sci., 110, No. 1, 47-54 (2009).
C. Tulone, Y. Uchiyama, M. Novelli, et al., BMC Immunol., 8, 22 (2007).
A. Vashishta, S. S. Ohri, and V. Vetvicka, Endocr. Metab. Immune Disord. Drug Targets, 9, No. 4, 385-391 (2009).
A. Warren, V. Benseler, V. C. Cogger, et al., Toxicol. Pathol., 39, No. 2, 390-397 (2011).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 160, No. 7, pp. 34-37, July, 2015
Rights and permissions
About this article
Cite this article
Goncharova, N.V., Shurlygina, A.V., Mel’nikova, E.V. et al. Cellular Composition of the Spleen and Changes in Splenic Lysosomes in the Dynamics of Dyslipidemia in Mice Caused by Repeated Administration of Poloxamer 407. Bull Exp Biol Med 160, 28–31 (2015). https://doi.org/10.1007/s10517-015-3090-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-015-3090-7